News Bayer’s Stivarga fast-tracked for liver cancer review Bayer’s cancer treatment Stivarga has been granted priority review status by the FDA for use as a second line treatment of unresectable hepatocellular carcinoma (uHCC).
News Stanford and twoXAR strike deal to take on liver cancer Stanford University School of Medicine is to take on liver cancer by teaming with twoXAR to develop new drug candidates.
News NICE says no to liver cancer drug Nexavar Liver cancer treatment latest earmarked for removal from CDF
R&D LSX2026: On a therapeutic vision for ocular disease, with Al... Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
